Search our Database of Scientific Publications and Authors

I’m looking for a

    45187 results match your criteria Psoriasis

    1 OF 904

    Usefulness and Correlation With Clinical Response of Serum Ustekinumab Levels Measured at 6 Weeks Versus 12 Weeks.
    J Dermatolog Treat 2018 Apr 23:1-18. Epub 2018 Apr 23.
    a Dermatology Department , Hospital Universitario Germans Trias i Pujol , Badalona , Spain . Universitat Autònoma de Barcelona, Facultad de Medicina.
    Background: Monitoring serum drug levels has been proposed as a useful tool for improving and personalising the management of psoriasis. However, in the case of ustekinumab the usefulness of such monitoring was not demonstrated when drug levels were measured at week 12.

    Objectives: To evaluate the correlation of serum ustekinumab levels measured at weeks 6 and 12 with clinical response. Read More

    Immunogenicity of biologic therapies: causes and consequences.
    Expert Rev Clin Immunol 2018 Apr 23. Epub 2018 Apr 23.
    a Department of Pathology and Immunology, Faculty of Medicine , University of Geneva , Geneva , Switzerland.
    Introduction: Antibodies or fusion proteins termed biologics allow the targeted therapy of diseases. Many of these agents have proven superior efficacy and safety to conventional therapies, and subsequently revolutionized the management of numerous chronic diseases. Repetitive administration of these protein-based therapeutics to immunocompetent patients elicit immune responses in the form of Anti Drug Antibodies (ADAs), which in turn impact their pharmacological properties and may trigger adverse events. Read More

    Psoriasis as a cardiovascular risk factor: updates and algorithmic approach.
    G Ital Dermatol Venereol 2018 Apr 19. Epub 2018 Apr 19.
    Department of Dermatology, Policlinico San Martino, University of Genoa, Genoa, Italy.
    Although psoriasis is predominantly a chronic inflammatory skin disorder, it has been known to be associated with cardiovascular disease. Patients with psoriasis, particularly with moderate to severe forms, present an increased rate of cardiovascular mortality, myocardial infarction and stroke. However the pathophysiology of the relationship between psoriasis and cardiovascular risk and comorbidities has not yet completely known. Read More

    Computed tomography imaging findings in erythrodermic psoriasis treated with infliximab: A case report.
    Radiol Case Rep 2018 Apr 2;13(2):460-463. Epub 2018 Mar 2.
    Department of Radiology, Toshiba Hospital, Oimachi, Tokyo, 6-3-22 Oimachi, Shinagawa-ku, Tokyo 140-8522, Japan.
    Erythrodermic psoriasis (EP), 1 of the most rare and severe forms of psoriasis, is characterized by general erythema with silvery scales. Systemic vasodilatation in EP is potentially life-threatening, however, the degree and extent of inflammation in subcutaneous tissues are difficult to estimate accurately using standard skin inspections or ultrasound examinations. Computed tomography can be a useful modality in solving this problem. Read More

    A Case of Ceftriaxone-Induced Acute Generalized Exanthematous Pustulosis/Generalized Pustular Psoriasis Overlap.
    Case Rep Dermatol 2018 Jan-Apr;10(1):69-75. Epub 2018 Mar 27.
    Department of Dermatology, Shanghai Skin Disease Hospital, Shanghai, China.
    Acute generalized exanthematous pustulosis, characterized by subcorneal or superficial intraepidermal pustules, is induced by drugs in more than 90% of cases. Psoriasis is an autoimmune disease triggered by different conditions in genetically susceptible people. Generalized pustular psoriasis is an acute and severe clinical form of psoriasis, which usually occurs in patients with psoriasis undergoing aggravating factors. Read More

    Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose-response meta-analysis of prospective studies.
    Eur J Epidemiol 2018 Apr 21. Epub 2018 Apr 21.
    Department of Public Health and Nursing, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
    Greater body mass index (BMI) has been associated with increased risk of psoriasis in case-control and cross-sectional studies, however, the evidence from prospective studies has been limited. We conducted a systematic review and dose-response meta-analysis of different adiposity measures and the risk of psoriasis to provide a more robust summary of the evidence based on data from prospective studies. PubMed and Embase databases were searched for relevant studies up to August 8th 2017. Read More

    Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis.
    Biopharm Drug Dispos 2018 Apr 21. Epub 2018 Apr 21.
    Auckland Clinical Studies Ltd, Auckland, New Zealand.
    This study evaluated pharmacokinetics (PK), efficacy, safety, and tolerability of bleselumab - a fully-human anti-CD40 monoclonal recombinant IgG4. Patients with moderate-to-severe psoriasis were randomized on Day 1 to receive bleselumab or placebo on Days 1, 15, and 29 in a dose-escalation of bleselumab 0.1, 0. Read More

    Bariatric Surgery in Immunocompromised Patients: Outcomes from One Year Follow-up.
    Obes Surg 2018 Apr 20. Epub 2018 Apr 20.
    Yenepoya Research Centre, Yenepoya University, University Road, Mangalore, India.
    Background: Recent Research evidences from across the world indicate the usefulness of bariatric surgery in improving the immunological co-morbidities in patients with morbid obesity.

    Aim: The aim of the study was to evaluate the outcome from bariatric surgery in patients presenting with diabetes mellitus and or morbid obesity with immunological co-morbidities.

    Methods: It was a retrospective cross-sectional study. Read More

    The Therapeutic Potential and Molecular Mechanism of Isoflavone Extract against Psoriasis.
    Sci Rep 2018 Apr 20;8(1):6335. Epub 2018 Apr 20.
    School of Medicine, Fu Jen Catholic University, New Taipei City, 24205, Taiwan.
    Psoriasis is a common inflammatory disease. It affects 1-3% of the population worldwide and is associated with increasing medical costs every year. Typical psoriatic skin lesions are reddish, thick, scaly plaques that can occur on multiple skin sites all over the body. Read More

    Thromboxane A2 facilitates IL-17A production from Vγ4+ γδ T cells and promotes psoriatic dermatitis in mice.
    J Allergy Clin Immunol 2018 Apr 17. Epub 2018 Apr 17.
    Department of Dermatology, Kyoto University Graduate School of Medicine, Japan; Singapore Immunology Network (SIgN) and Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, IMMUNOS Building #3-4, Biopolis 138648, Singapore.
    Thromboxane A-TP signaling facilitates IL-17A production from dermal Vγ4 γδ T cells and promotes psoriatic dermatitis in mice. Regulation of TP activation may become a novel therapeutic target for psoriasis. Read More

    [Dermatologic toxicities of immune checkpoint inhibitors].
    Ann Dermatol Venereol 2018 Apr 17. Epub 2018 Apr 17.
    Oncodermatologie, institut universitaire du cancer Toulouse Oncopole, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France.
    The development of immune checkpoint inhibitors (monoclonal antibodies targeting PD-1/PD-L1 or CTLA-4) represents a significant advance in the treatment of multiple cancers. Given their particular mechanism of action, which involves triggering CD4+/CD8+ T-cell activation and proliferation, they are associated with a specific safety profile. Their adverse events are primarily immune-related, and can affect practically all organs. Read More

    An unexpected cause of sacroiliitis in a patient with gout and chronic psoriasis with inflammatory arthritis: a case report.
    BMC Musculoskelet Disord 2018 Apr 20;19(1):126. Epub 2018 Apr 20.
    Rheumatology Department, Cork University Hospital, Cork, Ireland.
    Background: Inflammatory back pain is a condition characterized by inflammation of the sacroiliac joints and lower spine. It is frequently seen in patients with spondyloarthropathies like ankylosing spondylitis, psoriatic arthritis, enteropathic arthritis and reactive arthritis. Inflammatory back pain can be caused by many other conditions like infection and crystal deposition such as gout. Read More

    Psoriasis Management in Actual Clinical Practice: A 6-Year Retrospective Study of 845 Patients.
    J Dermatolog Treat 2018 Apr 20:1-21. Epub 2018 Apr 20.
    b Department of Biostatistics , Ankara Yildirim Beyazit University Faculty of Medicine , Ankara , TURKEY.
    Background: Over the past years, with the availability of relatively well tolerated, very effective but expensive drugs, biologics, treatment of psoriasis has dramatically shifted from inpatient modalities to outpatient ones. Relatively little is known about true life practices regarding psoriasis treatment in our country.

    Aims: To assess the impact of introduction of conventional drugs and biological drugs on medical resource use of psoriasis patients. Read More

    Indirect co-cultures of healthy mesenchymal stem cells restore the physiological phenotypic profile of psoriatic mesenchymal stem cells.
    Clin Exp Immunol 2018 Apr 20. Epub 2018 Apr 20.
    Department of Clinical and Molecular Sciences - Dermatological Clinic, Università Politecnica delle Marche, via Tronto 10/a, 60126, Ancona, Italy.
    Psoriasis microenvironment, characterized by an imbalance between Th1/Th17 and Th2 cytokines, influences also mesenchymal stem cells (MSCs) phenotypic profile. MSCs from healthy donors (H-MSCs) can exert a strong paracrine effect by secreting active soluble factors, able to modulate the inflammation in the microenvironment. To evaluate the influence of H-MSCs on MSCs from psoriatic patients (PsO-MSCs), H-MSCs and PsO-MSCs were isolated and characterized. Read More

    Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab.
    J Dermatolog Treat 2018 Apr 20:1-13. Epub 2018 Apr 20.
    a Dermatology, Department of "Medicina dei Sistemi" , University of Rome "Tor Vergata" , Rome , Italy.
    Psoriasis tends to improve for approximately half of patients during pregnancy, but an equal number of patients report no change or worsening during this period, when lots of medications, like biologics, are not indicated. The aim of our study was to review data of patient that had been pregnant during ustekinumab treatment, analyzing data of our data set between September 2010 and February 2018. We found data of three patients that had been pregnant during ustekinumab treatment. Read More

    A retrospective observational study on biological drug treatment in a daily practice serving patients with psoriasis in Japan.
    J Dermatolog Treat 2018 Apr 20:1-17. Epub 2018 Apr 20.
    a Department of Dermatology , Kurume University School of Medicine , 67 Asahimachi , Kurume , Fukuoka 830-0011 , Japan.
    Background: In Japan, more than 5 years have passed since emergence of the first 3 biologics, infliximab, adalimumab, and ustekinumab, became available in daily practice; however, no data for drug survival was reported from Japan.

    Objective: To study the long-term drug survival of infliximab, adalimumab, and ustekinumab used for Japanese psoriatic patients.

    Methods: We retrieved data on all patients treated with biological agents and calculated the long-term drug survival for infliximab, adalimumab, and ustekinumab using our psoriasis registry (Kurume Psoriasis Registry: KURUPR) consisted of 343 patients by the end of March 2017. Read More

    Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate to severe plaque psoriasis.
    J Dermatolog Treat 2018 Apr 20:1-20. Epub 2018 Apr 20.
    a Pharmacy Department , Hospital General Universitario Gregorio Marañón , Madrid , Spain.
    Purpose: The aim of this study was to identify clinical factors associated with dose reduction and dose escalation in the treatment with ustekinumab in patients with moderate to severe plaque psoriasis.

    Materials And Methods: An observational, longitudinal and retrospective study was conducted using patients with moderate to severe plaque psoriasis. We reviewed clinical histories and variables were recorded on a database (patients' characteristics, pharmacotherapeutics, effectiveness and safety). Read More

    Spondyloarthritis, Acute Anterior Uveitis, and Fungi: Updating the Catterall-King Hypothesis.
    Front Med (Lausanne) 2018 5;5:80. Epub 2018 Apr 5.
    Department of Ophthalmology, Oregon Health and Science University, Portland, OR, United States.
    Spondyloarthritis is a common type of arthritis which affects mostly adults. It consists of idiopathic chronic inflammation of the spine, joints, eyes, skin, gut, and prostate. Inflammation is often asymptomatic, especially in the gut and prostate. Read More

    Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences.
    Front Immunol 2018 5;9:579. Epub 2018 Apr 5.
    Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
    Psoriasis is a common inflammatory skin disease characterized by the appearance of red scaly plaques that can affect any part of the body. High prevalence, chronicity, disfiguration, disability, and associated comorbidity make it a challenge for clinicians of multiple specialties. Likewise, its complex pathogenesis, comprising inflammation, hyperproliferation, and angioneogenesis, intrigues numerous scientific disciplines, namely, immunology. Read More

    A Case of Psoriasis Complicated by Breast Cancer after Systemic Treatments Including Biologics.
    Acta Med Okayama 2018 Apr;72(2):185-187
    Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558,
    Psoriasis is a common chronic inflammatory skin disorder that is characterized by scaly, erythematous, sharply demarcated plaques. The treatment for psoriasis has dramatically changed over the last 10 years with the introduction of biologics. However, the risk of cancer induced by biologics for psoriasis has not been fully analyzed, since these agents have such a short history of use. Read More

    Topically applied azaphenothiazines inhibit experimental psoriasis in mice.
    Int Immunopharmacol 2018 Apr 16;59:276-286. Epub 2018 Apr 16.
    University of Environmental and Life Sciences, Wrocław, Poland.
    The therapeutic efficacy of topically applied azaphenothiazine derivatives: 9-chloro-6-acetylaminobutylquinobenzo[3,2-b][1,4]thiazine (compound 4) and 6-chloroethylureidoethyldiquino[3,2-b;2';3'-e][1,4]thiazine (compound 5) in the amelioration of inflammatory symptoms of imiquimod-induced psoriasis in mice was investigated. Clobederm®, containing clobetasol propioniate, served as a reference drug. The application of the compounds led to thinning of the epidermis and reduction of the cell layers. Read More

    Microstructural alterations in the onychomycotic and psoriatic nail: relevance in drug delivery.
    Eur J Pharm Biopharm 2018 Apr 16. Epub 2018 Apr 16.
    Department of Pharmacology, Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, Spain; Industrial Pharmacy Institute, University of Santiago de Compostela, Spain.
    Despite the important nail alterations caused by onychomycosis and psoriasis few studies have characterized the microstructure of the diseased nail plate and the diffusion and penetration of drugs through this altered structure. This work aimed to characterize the microstructure of the healthy, onychomycotic and psoriatic human nail using Raman spectroscopy, scanning electron microscopy, optical microscope profilometry and mercury intrusion porosimetry followed by analysis of the structure with PoreCor® software. The results showed that onychomycotic nails have higher porosity and lower amounts of disulfide bonds compared to healthy nails. Read More

    Topical Janus Kinase Inhibitors: A Review of Applications in Dermatology.
    J Am Acad Dermatol 2018 Apr 16. Epub 2018 Apr 16.
    University of California, Irvine, Department of Dermatology, Irvine, CA, 92697.
    Background: Janus kinase inhibitors (JAKi) have attracted attention for their role in treating inflammatory disorders. This new class of biologics has the potential to significantly impact the field of dermatology, especially with the development of topical formulations.

    Objective: To summarize published evidence on the efficacy, safety, and tolerability of topical JAKi in the treatment of inflammatory skin conditions. Read More

    Diminished ovarian reserve in patients with psoriasis.
    Taiwan J Obstet Gynecol 2018 Apr;57(2):227-230
    Ufuk University, Faculty of Arts and Sciences, Department of Statistics Ankara, Turkey.
    Objective: Psoriasis is a multi-systemic chronic inflammatory skin disease. Previous data suggests that women with some chronic inflammatory diseases have diminished ovarian reserve. This study explores ovarian reserve in patients with psoriasis. Read More

    Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).
    Br J Dermatol 2018 Apr 19. Epub 2018 Apr 19.
    University of São Paulo, Campinas, Brazil.
    This is the report from the fifth meeting of the Harmonising Outcome Measures for Eczema initiative (HOME V). The meeting was held on 12-14 June 2017 in Nantes, France, with 81 participants. The main aims of the meeting were (i) to achieve consensus over the definition of the core domain of long-term control and how to measure it and (ii) to prioritize future areas of research for the measurement of the core domain of quality of life (QoL) in children. Read More

    Effects of Etanercept on the Patient-Perceived Results (PROs) in Patients with Moderate-To-Severe Plaque Psoriasis: Systematic Review of the Literature and Meta-Analysis.
    J Dermatolog Treat 2018 Apr 19:1-20. Epub 2018 Apr 19.
    c Dermatology Service, Infanta Leonor University Hospital , Madrid , Spain.
    Purpose: To evaluate the efficacy of etanercept (ETN) compared with placebo for moderate-to-severe psoriasis regarding patients reported outcomes (PROs).

    Methods: Systematic review of studies retrieved by a sensitive search strategy in Medline, Embase, Cochrane Library.

    Selection Criteria: (population) studies had to include patients with for moderate-to-severe psoriasis; (intervention and control) studies had to test ETN vs placebo; and (outcomes), studies had to report PROs including quality of life, pain, pruritus or sleep. Read More

    Psoriatic Arthritis and Nail Psoriasis in a Patient with Concomitant Atopic Dermatitis.
    Case Rep Dermatol Med 2018 18;2018:4125856. Epub 2018 Feb 18.
    Department of Rheumatology, Hutt Hospital, Lower Hutt, New Zealand.
    Coincidence of psoriasis and atopic dermatitis (AD) is considered to be very rare, as a result of the different underlying immunopathology. This case report describes a patient with long history of atopy and AD who developed psoriatic nail changes and psoriatic arthritis (PsA). The patient's skin, however, revealed only eczematous lesions without manifestation of psoriasis. Read More

    Electrophilic properties of itaconate and derivatives regulate the IκBζ-ATF3 inflammatory axis.
    Nature 2018 Apr 18. Epub 2018 Apr 18.
    Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.
    Metabolic regulation has been recognized as a powerful principle guiding immune responses. Inflammatory macrophages undergo extensive metabolic rewiring marked by the production of substantial amounts of itaconate, which has recently been described as an immunoregulatory metabolite . Itaconate and its membrane-permeable derivative dimethyl itaconate (DI) selectively inhibit a subset of cytokines , including IL-6 and IL-12 but not TNF. Read More

    Tuberculosis associated with tumor necrosis factor-α antagonists, case description and analysis of reported cases in Colombia.
    Biomedica 2018 Mar 15;38(1):7-16. Epub 2018 Mar 15.
    Laboratorio de Patología, Clínica San José, San José de Cúcuta, Colombia.
    Tumor necrosis factor-α (TNF-α) is an important fundamental cytokine during the immune response against cancer and infections such as tuberculosis. This molecule also plays a key pathogenic role in complex and difficult-to-treat diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis and ulcerative colitis. The treatment of these diseases frequently needs TNF-α antagonists, which has been related to an increased risk of developing tuberculosis, mycoses, and other severe infections. Read More

    Evaluation of the effect of Pulsed Dye Laser on chronic Psoriatic plaque.
    J Dermatolog Treat 2018 Apr 18:1-23. Epub 2018 Apr 18.
    b Kafr Elzaeat General hospital Gharbia Egypt , Egypt.
    Psoriasis is one of the most prevalent immune mediated skin diseases. Selective vascular destruction by pulsed dye laser is considered one of effective laser treatments.

    Objective: Evaluation of the therapeutic effect of pulsed dye laser in treatment of chronic psoriatic plaque lesions and changes in human beta defensin-2 expression in the psoriatic patients before and after treatment, with correlation to the clinical improvement. Read More

    Frizzled-related proteins 4 (SFRP4) rs1802073G allele predicts the elevated serum lipid levels during acitretin treatment in psoriatic patients from Hunan, China.
    PeerJ 2018 13;6:e4637. Epub 2018 Apr 13.
    Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
    Background: Acitretin is a second-generation synthetic retinoid, and is widely used for treating the severe psoriasis vulgaris. However, it should be chosen with caution for its cardiovascular risk, and it is reported that acitretin may increase the serum lipids. The purpose of this study is to investigate the relationship between the Frizzled-related proteins 4 (SFRP4) rs1802073 polymorphism and the changes of serum lipids in Chinese psoriatic patients during the treatment with acitretin. Read More

    A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis.
    Case Rep Gastrointest Med 2018 15;2018:9679287. Epub 2018 Feb 15.
    Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
    Secukinumab is an interleukin-17 inhibitor used for the treatment of ankylosing spondylitis (AS), psoriasis, and psoriatic arthritis. The risk of exacerbating underlying inflammatory bowel disease (IBD) in patients being treated with secukinumab for other conditions is controversial. We document a patient with AS and previously undiagnosed IBD, found to be in a severe ulcerative colitis flare shortly after receiving the loading dose of secukinumab. Read More

    Psoriasis patients demonstrate HLA-Cw*06:02 allele dosage-dependent T cell proliferation when treated with hair follicle-derived keratin 17 protein.
    Sci Rep 2018 Apr 17;8(1):6098. Epub 2018 Apr 17.
    Institute of Biochemistry and Genetics Ufa Federal Research Centre of the Russian Academy of Sciences, 450054, Ufa, Bashkortostan, Russia.
    It is broadly accepted that psoriasis is an immune-mediated disease with a heritable component, but it is not clear what causes inflammation in the skin. Previous research suggests that fragments of the keratin 17 (K17) protein, which are constitutively expressed in hair follicles, could act as autoantigens. In this study, we synthesized the K17 protein from mRNA derived from hair follicles and tested whether it elicited T cell responses depending on the patient genotype at the major susceptibility locus HLA-Cw*06:02. Read More

    Glabridin, an isoflavan from licorice root, ameliorates imiquimod-induced psoriasis-like inflammation of BALB/c mice.
    Int Immunopharmacol 2018 Apr 14;59:243-251. Epub 2018 Apr 14.
    Institute of Natural Medicine & Green Chemistry, School of Chemical Engineering and Light Industry, Guandong University of Technology, Guangzhou, 510006, China. Electronic address:
    In this paper, we investigate the effect of glabridin (Glab) on psoriasis. We observed that Glab significantly suppressed the levels of nitric oxide (NO), NF-κB subunit p65, interleukin (IL)-6, and IL-1β in lipopolysaccharide (LPS)-stimulated HaCaT cells. In addition, Glab treatment reduced the expression of IL-17A, IL-22, and IL-23 in TNF-α-stimulated-HaCaT cells. Read More

    The role of cytokines in T-cell memory in health and disease.
    Immunol Rev 2018 May;283(1):176-193
    Department of Immunology, University Hospital Zurich, Zurich, Switzerland.
    Upon stimulation with their cognate antigen, naive T cells undergo proliferation and differentiation into effector cells, followed by apoptosis or survival as precursors of long-lived memory cells. These phases of a T-cell response and the ensuing maintenance of memory T cells are shaped by cytokines, most notably interleukin-2 (IL-2), IL-7, and IL-15 that share the common γ chain (γ ) cytokine receptor. Steady-state production of IL-7 and IL-15 is necessary for background proliferation and homeostatic survival of CD4 and CD8 memory T cells. Read More

    Dyslipidaemia & oxidative stress in patients of psoriasis: Emerging cardiovascular risk factors.
    Indian J Med Res 2017 Dec;146(6):708-713
    Department of Medicine, University College of Medical Sciences (University of Delhi), Delhi, India.
    Background & Objectives: Psoriasis is a recurrent hyper-proliferative skin disease which is often associated with free radical generation, abnormal lipid metabolism and increased inflammatory secretion that induce cardiovascular risk in these patients. The present study was intended to evaluate serum lipids, lipoprotein and oxidants-antioxidants status and to establish their relationship with atherogenic risk markers [oxidized low-density lipoprotein (oxLDL) and high-sensitivity C-reactive protein (hsCRP)] in patients with psoriasis.

    Methods: The study was conducted on 150 psoriasis patients and 150 age- and sex-matched healthy controls. Read More

    Role of Angiogenenic Growth Factors In Psoriasis: A Review.
    Curr Drug Metab 2018 Apr 16. Epub 2018 Apr 16.
    Department of Human Genetics, Punjabi University, Patiala- 147002. India.
    Background: Psoriasis is a chronic inflammatory disease, involving autoimmune mechanism wherein immune system, autoantigens and various environmental triggers all interact to create the systemically diseased state. It is a multifactorial skin disease of complex nature characterized by infiltration of multiple immune cells, kerationcyte proliferation, and increased dermal vascularity. Among all factors, vascular alterations present a significant feature of the disease and angiogenesis seems to have an important role in giving rise to psoriasis phenotype. Read More

    Murine models of psoriasis and their usefulness for drug discovery.
    Expert Opin Drug Discov 2018 Apr 17:1-12. Epub 2018 Apr 17.
    a Research Center for Food and Cosmetic Safety and Research Center for Chinese Herbal Medicine , Chang Gung University of Science and Technology , Taoyuan , Taiwan.
    Introduction: Psoriasis is an autoimmune skin disease characterized by red plaques with silver or white multilayered scales with a thickened acanthotic epidermis. Using mouse models of cutaneous inflammation, IL-23/Th17 was identified to have a potential key role in psoriasis. New treatments to slow this inflammatory skin disorder are urgently needed. Read More

    Psoriasis and Cardiovascular Diseases: A Literature Review to Determine the Causal Relationship.
    Cureus 2018 Feb 15;10(2):e2195. Epub 2018 Feb 15.
    James K. Elrod Department of Health Administration, Louisiana State University, Shreveport, LA.
    Psoriasis is a chronic, complex autoimmune disease characterized by erythematous, scaly patches over extensor aspects of skin and is associated with joint involvement in about one-third of patients. An association between psoriasis and cardiovascular diseases (CVD) has been a topic of dilemma, and many studies have shown an increased risk of cardiovascular morbidity in patients with psoriasis. There is increasing evidence that psoriasis is associated with higher risk of CVD and increased prevalence of cardiovascular risk factors, as compared with the general population. Read More

    Willingness to trade-off: An intermediate factor in patient decision-making regarding escalating care.
    Health Psychol Open 2018 Jan-Jun;5(1):2055102918767718. Epub 2018 Apr 4.
    VA Connecticut Healthcare System, USA.
    This study aimed to evaluate treatment necessity, treatment concern, and willingness to engage in decisional trade-offs in the context of treatment escalation decision-making. Participants ( = 147) recruited online were randomized to read a vignette about escalating care in psoriasis in a 2 (high treatment concern vs moderate treatment concern) × 2 (high perceived treatment necessity vs moderate perceived treatment necessity) design. High treatment concern was associated with choosing to defer treatment escalation and being unwilling to engage in decisional trade-offs if disease risk changed. Read More

    Extra-intestinal manifestations of non-celiac gluten sensitivity: An expanding paradigm.
    World J Gastroenterol 2018 Apr;24(14):1521-1530
    Section of Gastroenterology, Department of Emergency and Organ Transplantation, University "Aldo Moro" of Bari, Bari 70124, Italy.
    Non celiac gluten sensitivity (NCGS) is a syndrome characterized by a cohort of symptoms related to the ingestion of gluten-containing food in subjects who are not affected by celiac disease (CD) or wheat allergy. The possibility of systemic manifestations in this condition has been suggested by some reports. In most cases they are characterized by vague symptoms such as 'foggy mind', headache, fatigue, joint and muscle pain, leg or arm numbness even if more specific complaints have been described. Read More

    Differential glucose requirement in skin homeostasis and injury identifies a therapeutic target for psoriasis.
    Nat Med 2018 Apr 16. Epub 2018 Apr 16.
    Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, USA.
    Proliferating cells, compared with quiescent cells, are more dependent on glucose for their growth. Although glucose transport in keratinocytes is mediated largely by the Glut1 facilitative transporter, we found that keratinocyte-specific ablation of Glut1 did not compromise mouse skin development and homeostasis. Ex vivo metabolic profiling revealed altered sphingolipid, hexose, amino acid, and nucleotide metabolism in Glut1-deficient keratinocytes, thus suggesting metabolic adaptation. Read More

    RIPK1 downregulation in keratinocyte enhances TRAIL signaling in psoriasis.
    J Dermatol Sci 2018 Apr 10. Epub 2018 Apr 10.
    Department of Dermatology, Asahikawa Medical University, Japan.
    Background: Psoriasis, a common inflammatory skin disorder characterized by scaly erythema and plaques, is induced by dysregulation of dendritic cell- and T cell-mediated immune reaction. Receptor-interacting protein kinase 1 (RIPK1) regulates inflammatory signaling in response to stimuli such as TNF-α, TRAIL, and TLRs, resulting in apoptosis, necroptosis and NF-κB activation. However, the physiological relevance in human epidermis remains elusive. Read More

    Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results Through 48 Weeks of a Phase 3, Multicenter, Randomized, Double-Blinded, Etanercept- and Placebo-Controlled Study (CIMPACT).
    J Am Acad Dermatol 2018 Apr 13. Epub 2018 Apr 13.
    University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
    Background: Phase 2 psoriasis studies with the Fc-free, PEGylated, anti-tumor necrosis factor biologic certolizumab pegol demonstrated meaningful clinical activity.

    Objective: Assess safety and efficacy of certolizumab in adults with moderate-to-severe chronic plaque psoriasis.

    Methods: Patients were randomized 3:3:1:3 to certolizumab 400 mg, 200 mg, or placebo every 2 weeks for 16 weeks or etanercept 50 mg twice-weekly for 12 weeks. Read More

    Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results through 48 Weeks from Two Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2).
    J Am Acad Dermatol 2018 Apr 13. Epub 2018 Apr 13.
    Dermatologikum Hamburg and SCIderm Research Institute, Hamburg, Germany.
    Background: Certolizumab pegol, the only Fc-Free, PEGylated anti-tumor necrosis factor biologic, demonstrated clinically meaningful improvements and suggested a positive risk-benefit balance in phase 2 studies in adults with moderate-to-severe chronic plaque psoriasis.

    Objective: Assess certolizumab efficacy and safety versus placebo in phase 3 studies.

    Methods: Patients with moderate-to-severe chronic plaque psoriasis were randomized 2:2:1 to certolizumab 400 mg, 200 mg, or placebo every 2 weeks. Read More

    1 OF 904